 |
Gatifloxacin (Image: bms) |
Gatifloxacin, one of the most widely prescribed antibiotics in North America, may increase the risk of life-threatening blood sugar abnormalities, according to a large-scale study conducted by Canadian scientists.
The study found that the antibiotic gatifloxacin, marketed under the brand name Tequin by Bristol-Myers Squibb, is associated with both increased and decreased blood sugar levels compared to other antibiotics.
Dr. David Juurlink, a researcher at the Institute for Clinical Evaluative Sciences (ICES) in Toronto, stated: “We found that individuals using gatifloxacin were four times more likely to be hospitalized for low blood sugar compared to those using other antibiotics. Additionally, those using gatifloxacin had a 17 times higher risk of high blood sugar.”
K.NHẬT
